Bromantane Overview, Dosing & Safety | Peptide Database

Bromantane (Ladasten)

Actoprotector | Dopamine Upregulation & Adaptive Energy

Community Research

Join others researching Bromantane — share findings, ask questions, and learn from real experiences

Bromantane (Ladasten) is a synthetic adamantane derivative developed in Russia during the 1980s as part of a military research program aimed at improving soldiers' physical and mental performance under extreme conditions. It was officially registered in Russia in 2002 as an anxiolytic and actoprotector -- a pharmacological class defined by the ability to enhance physical work capacity and mental performance under stressful conditions without the hyperactivation or crash associated with traditional stimulants. Unlike amphetamines, methylphenidate, or modafinil, bromantane does not directly block reuptake or trigger release of monoamines. Instead, it upregulates the gene expression of key enzymes in the dopamine biosynthetic pathway, producing a sustained, physiological increase in dopamine availability. This mechanism gives it a uniquely smooth, non-depleting profile that has made it increasingly popular in the international nootropic community for sustained cognitive energy, motivation, and stress resilience.

Bromantane's mechanism of action is fundamentally different from conventional stimulants and most nootropic compounds. Its primary action is the upregulation of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AADC) gene expression in the striatum and other dopaminergic brain regions. Tyrosine hydroxylase is the rate-limiting enzyme in dopamine synthesis, converting L-tyrosine to L-DOPA, while AADC converts L-DOPA to dopamine. By increasing the transcription of these enzymes, bromantane enhances the brain's endogenous capacity to produce dopamine rather than forcing release of existing stores or blocking their reuptake. This results in a gradual, sustained elevation of dopaminergic tone without the rapid depletion, tolerance, or rebound effects characteristic of releasers or reuptake inhibitors. Additionally, bromantane has documented anxiolytic properties, likely mediated through GABAergic facilitation and modulation of hippocampal activity, which contribute to its stress-protective and actoprotective effects. The compound also demonstrates mild serotonergic activity, which may further support its anxiolytic profile. This dual action -- enhanced dopaminergic drive combined with anxiolysis -- is what distinguishes bromantane from virtually all other cognitive enhancers and gives it the 'calm energy' quality users frequently describe.

Molecular Data

Research Indications

By increasing dopamine synthesis capacity, bromantane enhances baseline motivation, initiative, and the ability to engage in and sustain effortful tasks. Users consistently report improved ability to start and complete demanding cognitive work.

Provides a clean, non-jittery mental energy that supports prolonged cognitive effort. Unlike stimulants that front-load neurotransmitter release and lead to a crash, bromantane's gene-expression-level mechanism delivers steady-state enhancement over the course of the day.

The combination of dopaminergic upregulation and anxiolytic activity makes bromantane particularly useful for maintaining cognitive performance during periods of high psychological or physical stress.

Approved in Russia for the treatment of asthenic disorders with anxiety. Clinical trials demonstrated significant reductions in anxiety scores without the sedation, cognitive dulling, or dependence potential of benzodiazepines.

Primary approved indication in Russia. Bromantane addresses the fatigue, reduced drive, and emotional instability characteristic of asthenic conditions, restoring normal energy and emotional regulation.

As an actoprotector, bromantane improves physical endurance and recovery under conditions of heat stress, sleep deprivation, and sustained exertion. Originally developed for military applications requiring sustained physical output in adverse environments.

Some evidence suggests improved recovery from physical exertion, likely related to both the dopaminergic enhancement of central drive and the anxiolytic reduction of stress-mediated cortisol elevation.

Dosing Protocols

Bromantane is available in oral tablet and capsule form. It is lipophilic and absorbed through the gastrointestinal tract, though bioavailability data in humans is limited. Peak effects are typically felt within 1-2 hours of oral ingestion. Taking it with a fat-containing meal may improve absorption. Sublingual administration is also used by some individuals to improve onset speed and bioavailability, particularly with solution-based preparations.

Standard Nootropic

50 mg

Once daily in the morning

Oral or sublingual

Full Dose

100 mg

Sublingual (Enhanced Absorption)

50-100 mg

Sublingual (solution or powder held under tongue)

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Insomnia or difficulty falling asleep (if taken too late in the day)

Mild anxiety or restlessness at higher doses (above 100 mg)

Mild headache (uncommon, typically transient)

Stop Signs - Discontinue if:

Persistent anxiety or agitation that does not resolve with dose reduction

Any signs of allergic reaction (rash, swelling, difficulty breathing)

Significant sleep disruption despite morning-only dosing

Jaundice or signs of hepatic dysfunction

Contraindications

Known hypersensitivity to bromantane or adamantane derivatives

Pregnancy and breastfeeding (insufficient safety data)

Severe hepatic impairment

Concurrent use of MAO inhibitors (theoretical risk of excessive dopaminergic activity)

Frequently Asked Questions

Is bromantane a stimulant like Adderall or modafinil?

No. Bromantane does not directly block dopamine reuptake or force release like stimulants. Instead, it upregulates tyrosine hydroxylase gene expression to enhance endogenous dopamine synthesis capacity. This produces 'calm energy' without jitteriness, crash, or tolerance—a fundamentally different mechanism from conventional stimulants.

Can I combine bromantane with modafinil?

Use caution. Both enhance dopaminergic signaling through distinct mechanisms (bromantane via TH upregulation, modafinil via DAT inhibition). Combining them may result in excessive dopaminergic stimulation causing anxiety, overstimulation, or insomnia. If combining, start with lower doses of each and monitor closely.

Does bromantane cause tolerance like other dopamine-enhancing drugs?

No. Unlike dopamine reuptake inhibitors that lose efficacy as the brain downregulates receptors, bromantane's gene-expression mechanism means it becomes more effective over time as enzyme levels increase. Tolerance is minimal, and many users report that effects improve rather than diminish over the first 1-2 weeks.

What's the ideal cycle protocol for bromantane?

Typical nootropic cycles are 2-4 weeks on followed by 1-2 weeks off, though this is based more on tradition than necessity given the absence of tolerance or HPTA suppression. Some users cycle continuously. The 11-hour half-life supports once-daily morning dosing to avoid evening stimulation.

References

Demonstrated that bromantane (Ladasten) modulates gene expression related to dopaminergic neurotransmission in cortical brain regions, supporting the mechanism of action based on upregulation of dopamine biosynthetic enzymes rather than acute monoamine release.

Characterized bromantane as an actoprotector -- a compound that enhances physical work capacity without the exhaustion-inducing effects of psychostimulants. Documented its dual action as both an actoprotector and immunomodulator, and described its favorable safety and tolerability profile in clinical use.

Established that bromantane's primary pharmacological mechanism involves upregulation of tyrosine hydroxylase and AADC expression, leading to enhanced endogenous dopamine and serotonin biosynthesis. Confirmed that bromantane does not act as a dopamine reuptake inhibitor or releaser, distinguishing it mechanistically from classical psychostimulants.

Demonstrated bromantane's significant anxiolytic activity in multiple animal models of anxiety. Showed that the anxiolytic effect is mediated through GABAergic facilitation and modulation of hippocampal activity, confirming its dual action as both a dopaminergic enhancer and anxiolytic agent.

Phase III clinical trial demonstrating the efficacy and safety of Ladasten (bromantane) in patients with asthenic disorders. Showed significant improvements in fatigue, anxiety, and overall functioning compared to placebo, with excellent tolerability and no evidence of dependence or withdrawal, supporting its registration as an anxiolytic in Russia.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.